OXIS International, Inc. (OTCMKTS:OXIS) has been powering higher over the last few days, up over 100% in the past 3 sessions alone. We believe the primary catalyst is expectations of what may be discussed in a key conference call slated for Wednesday, August 16 ostensibly to discuss the upcoming merger of Georgetown Translation Pharmaceuticals, Inc. (GTP) and advancements made with the targeted immunotherapies currently in FDA clinical trials.
We believe in a basic credo: company’s don’t normally get really extroverted about current status updates on things like FDA trials and progressing mergers unless there are good updates to give. In other words, they are under no obligation to reveal how things are progressing, and yet they are choosing to, which likely represents good news on the way. The market sniffs the same thing, and we are seeing investors pile in ahead of that update.
OXIS International, Inc. (OTCMKTS:OXIS) frames itself as a company that, through its wholly owned subsidiary of Oxis Biotech, Inc., discovers, develops, and commercializes therapeutics from its proprietary product platform in various disease areas in the United States. The company is developing drugs focused on the treatment of cancer.
Its lead drug candidates include OXS-2175, a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer; OXS-4235, a small molecule therapeutic candidate to treat multiple myeloma and associated osteolytic lesion; and OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors.
GT Biopharma is in the process of completing the merger of Oxis International Inc. and Georgetown Translational Pharmaceuticals Inc. (GTP). The merger combines Oxis’ promising oncology drugs with GTP’s central nervous system drugs and GTP’s leadership team, which includes incoming CEO Dr. Clarence-Smith, an experienced pharmaceutical industry executive. The deal is expected to close before September 30.
OXIS was formerly known as DDI Pharmaceuticals, Inc. founded in 1965 and is based in Tampa, Florida.
According to company materials, “Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS’ lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.”
Subscribe below and we’ll keep you on top of what’s happening before $OXIS stock makes its next move.
As discussed above, the stock has been red hot, and this price rally coincides with the days leading up to a key update of the company’s merger process as it ingests GTP. It will also be updating how its targeted immunotherapies trials are progressing.
“The merger of GT Biopharma, Inc. (Oxis) and GTP will greatly accelerate the clinical development of exciting new treatments to meet the medical needs of those suffering from cancer and neurologic diseases,” said Dr. Clarence-Smith.
“The additions of the GTP pipeline and CEO Dr. Kathleen Clarence-Smith along with our new incoming CMO (formerly Chief Medical Officer, Oncology at Pfizer, Inc. (NYSE:PFE), will be instrumental in completing GT Biopharma/Oxis FDA phase 2 clinical trial and advance the highly sought after TriKE oncology platform technology from Dr. Jeff Miller of the University Of Minnesota Masonic Cancer Clinic.”
GT Biopharma Chairman and CEO Tony Cataldo stated, “There is a lot going on inside GT Biopharma (Oxis) and it is better to speak with our shareholders and market participants so everyone can understand what all of the excitement is about. Kathleen and I are pleased to make ourselves available to discuss the rationale of this merger.”
At this time, carrying a capital value in the market of $14.25M, OXIS has a bankroll ($235K) of cash on the books, which is balanced by about $11.8M in total current liabilities. The company is pre-revenue at this point. You can bet we will update this one again as new information comes into view. For continuing coverage on shares of $OXIS stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!
Disclosure: We hold no position in $OXIS, either long or short, and we have not been compensated for this article.